Stifel raised the firm’s price target on Travere Therapeutics (TVTX) to $25 from $20 and keeps a Hold rating on the shares following the announcement that FDA no longer plans to hold an advisory committee meeting for the sparsentan sNDA in focal segmental glomerulosclerosis. While the firm finds this “unexpected,” it notes that more recent precedent from FDA AdCom cancelations have been taken as positive indicators and is updating its model to reflect 90% odds of success of approval.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics falls -6.6%
- Travere Therapeutics price target raised to $35 from $27 at Wells Fargo
- Oracle surges on cloud outlook, Novo to cut 9,000 jobs: Morning Buzz
- Positive Outlook for Travere Therapeutics: Buy Rating Supported by FILSPARI’s Strong Data and Competitive Advantages
- AdCom cancellation ‘clear positive’ for Travere Therapeutics, says Jefferies